Project Grant R21AI183080
Award Date
11/13/24
Completion Date
10/31/26
Dollars Obligated
$284K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
This $986,387 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to identify cellular proteins associated with adeno-associated virus (AAV) genomes. The goal is to improve understanding of the cellular factors that interact with AAV genomes to facilitate gene expression, DNA replication, genome encapsidation, and vector transduction. The researchers will employ a novel proteomics technology to...
This $862,440 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund research to evaluate novel gene editing therapies targeting chronic hepatitis B virus (HBV) infection using a new humanized mouse model. The key objectives are to: 1) Assess the anti-HBV efficacy of different gene editing nuclease therapies delivered via adeno-associated virus (AAV) and lipid nanoparticles (LNPs) in the NSG-PIZ...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop virus-like particles (VLPs) as a delivery mechanism for therapeutic proteins to address the HIV/AIDS pandemic. The key objectives are to: 1) Use VLPs to deliver the HIV-1 Tat protein as a latency reversing agent, then target the reactivated cells for elimination using adeno-associated virus...
This R01 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $769,737 to Yale University for the development and testing of engineered adeno-associated viral (AAV) vectors. The goal is to deliver a novel gene therapeutic called BREC1 that can target and excise HIV-1 proviral DNA sequences from infected cells, as well as a BREC1-based epigenetic silencer to durably suppress...
This federal Project Grant award of $213,284 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to repurpose viral fusion machinery for delivering user-defined cargo to cells containing the appropriate receptors. The research will focus on several virus-derived proteins, including hemagglutinin (HA) from influenza, glycoprotein G (NIV-G) and fusion protein F (NIV-F) from Nipah virus, and the spike...
This federal Project Grant award in the amount of $1,486,800.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research to investigate the role of TNFRSF14 signaling in promoting antibody-dependent cell-mediated cytotoxicity (ADCC) for the development of a vaccine against herpes simplex virus (HSV). The research aims to define the signaling pathways and structural...
This federal Project Grant award, valued at $540,524 and effective from March 1, 2025 to February 28, 2029, was provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program. The primary objective of this award is to develop an enhanced RNA switch technology based on the T3H38 ribozyme, which can enable precise dose control and temporal regulation...
This $367,059 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to develop a better understanding of the genomic, epigenomic, and transcriptomic outcomes of gene therapy. The research aims to explore the long-term effects of vector integration, the impact of cell/tissue type and promoters on vector behavior, and the host response to different gene therapy delivery...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of self-recirculating, non-replicating bacteriophage (phage) vectors as a platform for targeted gene therapy of the human microbiome. The $233,250 award, effective from May 13, 2025 to April 30, 2027, aims to produce and characterize various self-contained non-replicative phage vectors (SCNRPVs) and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to improve the understanding of how antibodies can control viral infections through Fc-dependent mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytolysis (CDC). The $318,085 award, effective from December 23, 2024 to...